CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Sector revisions Charles River Laboratories International, Inc.
Equities
CRL
US1598641074
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 205.79 USD | -1.83% |
|
+3.62% | -12.95% |
| 01:49pm | Baird Adjusts Charles River Laboratories International Price Target to $190 From $191 | MT |
| Sep. 17 | Charles River Laboratories, CEBINA Partner to Accelerate Neurodegenerative Drug Development | MT |
Main competitors
| 1m. EPS revision | 1m. Revenue rev. | 4m. EPS revision | 4m. Revenue rev. | 1y. EPS revision | 1y. Revenue rev. | Divergence of Estimates | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
| 17 | |||||||||
| 21 | |||||||||
| 21 | |||||||||
| 27 | |||||||||
| 19 | |||||||||
| 19 | |||||||||
| 16 | |||||||||
| 13 | |||||||||
| 13 | |||||||||
| 9 | |||||||||
| 17 | |||||||||
| - | - | - | 8 | ||||||
| 14 | |||||||||
| 25 | |||||||||
| 6 | |||||||||
| 17 | |||||||||
| 16 | |||||||||
| 12 | |||||||||
| 13 | |||||||||
| Average | 16 | ||||||||
| Weighted average by Cap. | 18 |
